iRadimed Quarterly Income Statement
NASDAQ: IRMDHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
iRadimed revenue and earnings
In the quarter ended Jun 30, 2026, iRadimed generated $20.5 million in revenue, up 0.3% from the same quarter a year earlier. Net income was $5.2 million (-9.6% year over year), for a net margin of 25.5% versus a median of 26.5% in the prior 5 quarters. Gross margin was 74.1% (down from 78.2%) and operating margin 31.2%.
Diluted earnings per share came in at $0.41, down from $0.45.
Summary generated from market data by MetaCap's automated system. Methodology
iRadimed income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.47M | 21.98M | 22.69M | 21.20M | 20.41M | 19.51M | 19.39M | 18.33M | 17.93M | 17.60M | 17.45M | 16.50M |
| Revenue growth (YoY) | +0.28% | +12.65% | +17.03% | +15.69% | +13.83% | +10.87% | +11.10% | +11.04% | +11.15% | +13.72% | +17.42% | +23.10% |
| Cost of Revenue | 5.31M | 5.17M | 5.66M | 4.71M | 4.45M | 4.67M | 4.63M | 4.13M | 3.92M | 4.21M | 4.04M | 3.67M |
| Gross Profit | 15.16M | 16.81M | 17.03M | 16.49M | 15.96M | 14.84M | 14.76M | 14.19M | 14.01M | 13.39M | 13.41M | 12.84M |
| Operating Expenses | 8.77M | 9.58M | 9.94M | 9.66M | 9.17M | 9.41M | 8.96M | 8.40M | 8.38M | 8.64M | 8.25M | 6.93M |
| Research & Development | 657.00K | 956.00K | 799.03K | 674.36K | 877.00K | 624.00K | 570.40K | 639.47K | 801.13K | 821.00K | 650.43K | 452.56K |
| Selling, General & Admin | 8.11M | 8.62M | 9.14M | 8.99M | 8.29M | 8.79M | 8.39M | 7.76M | 7.58M | 7.82M | 7.60M | 6.48M |
| Operating Income | 6.39M | 7.24M | 7.09M | 6.83M | 6.79M | 5.43M | 5.80M | 5.79M | 5.63M | 4.75M | 5.16M | 5.91M |
| Other Income (Expense) | 497.00K | 532.00K | 696.80K | 463.98K | 539.00K | 513.00K | 543.43K | 629.20K | 642.22K | 495.15K | 521.81K | 503.19K |
| Pretax Income | 6.89M | 7.77M | 7.79M | 7.30M | 7.33M | 5.95M | 6.34M | 6.42M | 6.27M | 5.24M | 5.68M | 6.41M |
| Income Tax | 1.67M | 1.95M | 1.35M | 1.72M | 1.55M | 1.26M | 1.20M | 1.37M | 1.37M | 1.11M | 1.14M | 1.34M |
| Net Income | 5.22M | 5.82M | 6.44M | 5.58M | 5.77M | 4.69M | 5.15M | 5.05M | 4.90M | 4.14M | 4.54M | 5.07M |
| Net Income growth (YoY) | -9.63% | +24.13% | +25.17% | +10.44% | +17.81% | +13.31% | +13.37% | -0.35% | +17.26% | +21.45% | +23.58% | +47.86% |
| EPS (Basic) | 0.41 | 0.46 | 0.51 | 0.44 | 0.45 | 0.37 | 0.40 | 0.40 | 0.39 | 0.33 | 0.36 | 0.40 |
| EPS (Diluted) | 0.41 | 0.45 | 0.50 | 0.43 | 0.45 | 0.37 | 0.40 | 0.40 | 0.38 | 0.32 | 0.35 | 0.40 |
| Shares Outstanding (Basic) | 12.78M | 12.78M | — | 12.72M | 12.72M | 12.71M | — | 12.67M | 12.66M | 12.66M | — | 12.60M |
| Shares Outstanding (Diluted) | 12.87M | 12.87M | — | 12.86M | 12.84M | 12.83M | — | 12.78M | 12.76M | 12.75M | — | 12.74M |
| EBITDA | 6.80M | 7.69M | 7.47M | 7.22M | 7.00M | 5.63M | 6.00M | 5.99M | 5.83M | 4.97M | 5.37M | 6.10M |
| Gross Margin | 74.07% | 76.50% | 75.06% | 77.80% | 78.18% | 76.08% | 76.13% | 77.44% | 78.14% | 76.07% | 76.86% | 77.78% |
| Operating Margin | 31.23% | 32.93% | 31.26% | 32.23% | 33.26% | 27.84% | 29.92% | 31.59% | 31.39% | 26.98% | 29.57% | 35.78% |
| Net Margin | 25.50% | 26.47% | 28.39% | 26.30% | 28.29% | 24.02% | 26.54% | 27.55% | 27.34% | 23.51% | 26.01% | 30.70% |
This table shows 12 quarterly periods of iRadimed's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow IRMD's reporting calendar. What is a income statement?